Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A new study shows that a conservative approach to revascularization for patients with intermediate coronary lesions determined by angiographic diameter stenosis is safe and non-inferior to an aggressive approach. Findings of the SMART-CASE trial were presented at the 25th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.
Angiographic diameter stenosis (DS) is the most widely used criteria to perform percutaneous coronary intervention in daily practice. While DS between 50 and 70 percent has been termed an "intermediate stenosis," the clinical outcome of PCI based on the angiographic criteria of 50 percent or 70 percent has never been studied.
The SMART-CASE trial evaluated the relative efficacy and safety of a conservative revascularization strategy for intermediate stenoses compared to a more aggressive approach of anatomical complete revascularization in the treatment of coronary stenosis. The investigator-initiated, multicenter, open label, prospective trial randomized 899 patients undergoing coronary angiography to be evaluated for PCI based on a conservative strategy (revascularization of DS>70 percent) or an aggressive strategy (DS>50 percent). The primary endpoint was a composite of all cause death, myocardial infarction or any revascularization at one year.
After one year, both the conservative strategy group and aggressive strategy group had similar rates of adverse events (7.3 percent vs. 6.8 percent, respectively). Rates for all cause death (0.5 percent vs. 2.1 percent), myocardial infarction (0.9 percent in each group) and any revascularization (6.8 percent vs. 4.8 percent) were also similar, demonstrating the non-inferiority of the conservative strategy.
"Conservative revascularization using criteria of 70 percent diameter stenosis was found to be non-inferior to aggressive revascularization," said the lead investigator Hyeon-Cheol Gwon, MD, PhD. Dr. Gwon is a Professor at the Samsung Medical Center in Seoul, South Korea.
"These results demonstrate that revascularization of angiographically intermediate lesions can be safely deferred."
The SMART-CASE trial was funded by Sungkyunkwan University Foundation for Corporate Collaboration (Seoul, Korea) and Abbott Vascular Korea (Seoul, Korea.) Dr. Gwon reported research support from Abbott Vascular Korea and Medtronic Korea; and consulting fees from Medtronic Asia Pacific.
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Cardiovascular / Cardiology category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Cardiovascular Research Foundation. "Conservative and aggressive revascularization strategies for coronary stenting compared: SMART-CASE trial results." Medical News Today. MediLexicon, Intl., 2 Nov. 2013. Web.
11 Dec. 2013. <http://www.medicalnewstoday.com/releases/268201>
Cardiovascular Research Foundation. (2013, November 2). "Conservative and aggressive revascularization strategies for coronary stenting compared: SMART-CASE trial results." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/268201.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.